Literature DB >> 15086938

FGF-23 in patients with end-stage renal disease on hemodialysis.

Yasuo Imanishi1, Masaaki Inaba, Kiyoshi Nakatsuka, Kyoko Nagasue, Senji Okuno, Asami Yoshihara, Masakazu Miura, Akimitsu Miyauchi, Keisuke Kobayashi, Takami Miki, Tetsuo Shoji, Eiji Ishimura, Yoshiki Nishizawa.   

Abstract

BACKGROUND: Fibroblast growth factor (FGF)-23 is a recently identified circulating factor which causes renal phosphate wasting disorders. Although the mechanism of regulation of FGF-23 secretion is unknown, plasma FGF-23 level may be regulated or affected by serum phosphate levels because of its hypophosphatemic effect.
METHODS: We tested the hypothesis that plasma FGF-23 levels may be increased in hyperphosphatemia in patients with end-stage renal disease (ESRD) on maintenance hemodialysis. We measured plasma FGF-23 levels in 158 male uremic patients on maintenance hemodialysis. Plasma samples were obtained before starting dialysis sessions to determine FGF-23 levels by enzyme-linked immunosorbent assay (ELISA).
RESULTS: Plasma FGF-23 level exhibited significant and positive correlations with inorganic phosphate, intact parathyroid hormone (PTH), corrected calcium, and duration of hemodialysis on simple regression analyses. All these associations remained significant in multiple regression analyses.
CONCLUSION: Serum phosphate, calcium, and intact PTH could be regulators of FGF-23 levels in uremic patients on maintenance hemodialysis. Our results may provide new insights into the pathophysiologic effects of FGF-23 on calcium-phosphate homeostasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15086938     DOI: 10.1111/j.1523-1755.2004.00604.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  80 in total

Review 1.  Vitamin D: roles in renal and cardiovascular protection.

Authors:  Yan C Li
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

Review 2.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

Review 3.  Is Fibroblast Growth Factor-23 a novel marker for phosphate burden in chronic kidney disease with prognostic implications?

Authors:  Bernhard Bielesz
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

4.  Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy.

Authors:  Julia M Hum; Linda M O'Bryan; Arun K Tatiparthi; Erica L Clinkenbeard; Pu Ni; Martin S Cramer; Manoj Bhaskaran; Robert L Johnson; Jonathan M Wilson; Rosamund C Smith; Kenneth E White
Journal:  J Appl Physiol (1985)       Date:  2019-01-03

5.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.

Authors:  Despina Sitara; Mohammed S Razzaque; Martina Hesse; Subbiah Yoganathan; Takashi Taguchi; Reinhold G Erben; Harald Jüppner; Beate Lanske
Journal:  Matrix Biol       Date:  2004-11       Impact factor: 11.583

6.  Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility.

Authors:  Keith G Avin; Julian A Vallejo; Neal X Chen; Kun Wang; Chad D Touchberry; Marco Brotto; Sarah L Dallas; Sharon M Moe; Michael J Wacker
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-03-20       Impact factor: 4.310

7.  High calcium diet alleviates 5/6 nephrectomy-induced bone deteriorations of lumbar vertebrae in mice.

Authors:  Hai-Tao Hou; Ya-Nan Wang; Shi-Ze Shao; Song Fu; Xiang-Peng Huang; Xiao-Hui Wang
Journal:  Exp Ther Med       Date:  2018-02-14       Impact factor: 2.447

8.  Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.

Authors:  P Manghat; W D Fraser; A S Wierzbicki; I Fogelman; D J Goldsmith; G Hampson
Journal:  Osteoporos Int       Date:  2009-12-09       Impact factor: 4.507

Review 9.  Chronic dialysis in patients with end-stage renal disease: Relevance to kidney xenotransplantation.

Authors:  Abhijit Jagdale; David K C Cooper; Hayato Iwase; Robert S Gaston
Journal:  Xenotransplantation       Date:  2018-11-20       Impact factor: 3.907

10.  Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

Authors:  James B Wetmore; Shiguang Liu; Ron Krebill; Rochelle Menard; L Darryl Quarles
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-05       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.